Cardiovascular and Metabolic Disorders

CARDIOVASCULAR AND METABOLIC DISORDERS

Featured Article

2015 saw a great leap forward in the development and use of PCSK9 (proprotein convertase subtilisin/kexin) inhibitors. This past July, the FDA approved alirocumab (Praluent, Regeneron), followed 1 month later by the approval of a second PCSK9 inhibitor evolocumab (Repatha, Amgen). The drugs were approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or those with clinical atherosclerotic cardiovascular disease requiring additional LDL-C lowering. A third drug, bococizumab (Pfizer), is currently in development. Data from large, long-term randomized controlled outcomes trials—ODYSSEY Outcomes (alirocumab), FOURIER (evolocumab), and SPIRE (bococizumab)—are anticipated to provide clear answers as to the drugs' impact on cardiovascular events and safety profiles. –from "The Promise of PSCK9 Inhibitors by Brian Ellis,” published 11/9/15.

Expert Q&A: Reassessing Risk-Based LDL-C Targets

By

Tori Rodriguez, MA, LPC, AHC

Lipid-lowering therapies are key to the prevention of cardiovascular (CV) events and CV-related mortality.

Latest News

Achieving Optimal Population Cardiovascular Health: An AHA Scientific Statement

By

Colby Stong

Improving the cardiovascular health of patients and the general population requires increased primordial and primary prevention efforts.

SGLT2 Inhibitor Reduces BP Without Changing Sodium Excretion

By

Lauren Biscaldi

Researchers studied the effect of dapagliflozin on cumulative sodium excretion in patients with type 2 diabetes and preserved kidney function while sodium intake was being strictly controlled.

menopause, hot flash

AHA Scientific Statement on Prevention of CVD Risk During Menopause Transition

By

Gary Rothbard MD, MS

Scientific statement by AHA detailing the current understanding of menopause transition and its impact on the risk for postmenopausal cardiovascular disease.

ASCVD CHD Risk Familial Hypercholesterolemia

Evinacumab Lowers LDL Cholesterol in Refractory Hypercholesterolemia

By

Jessica Nye, PhD

In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.

Cardiovascular Risk Increased With Metabolic Syndrome in Psoriasis

Metabolic syndrome (MetSyn) is prevalent among patients with psoriasis and is associated with increased cardiovascular risk.

Sucrose Produces Lower Increases in Satiety Signaling Hormones Vs Glucose

By

Brandon May

Sucrose, or common table sugar, is not as effective as glucose in signaling postprandial satiation.

Recommended Follow-Up Care Not Given After Bariatric Surgery

Many bariatric surgery patients do not receive recommended postoperative nutritional and weight monitoring within general practice.

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN

Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism.

Cholesterol bloodstream

Inclisiran Approval Held Up by Inspection-Related Issues

By

Diana Ernst, RPh

Inclisiran is a chemically synthesized small interfering RNA that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.

Remnant Cholesterol Concentration an Independent Predictor of Poor CV Outcomes

By

Jessica Nye, PhD

Poor cardiovascular outcomes are more likely in patients with elevated remnant cholesterol or triglycerides.

Weight Loss in Morbid Obesity Not Equivalent Between LSG and LRYGB

Laparoscopic Roux-en-Y gastric bypass results in greater weight loss than laparoscopic sleeve gastrectomy seven years after surgery.

Next post in Cardiovascular and Metabolic Disorders

menopause, hot flash

AHA Scientific Statement on Prevention of CVD Risk During Menopause Transition